首頁 > 市場調查報告書 > 製藥

化學品酵素

市場調查報告書

商品編碼

2050751

血管收縮素轉化酵素(ACE) 抑制劑市場：依藥物、適應症、給藥途徑、通路和地區分類

Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，血管收縮素轉化酵素(ACE) 抑制劑市場規模將達到 95.223 億美元，到 2033 年將達到 141.3 億美元。 2026 年至 2033 年的年複合成長率（CAGR）預計為 5.8%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	95.223億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	5.80%	2033年市場規模預測：	141.3億美元

血管收縮素轉化酵素（ACE）抑制劑是一類主要用於治療高血壓和心臟衰竭的藥物。它們透過抑制一種名為血管收縮素II的激素的作用來發揮作用。血管收縮素II會收縮血管並促進醛固酮的釋放，導致體內水分和鹽分儲存。 ACE抑制劑抑制血管收縮素II的生成，使血管舒張，減少體內水分儲存，最後降低血壓。常用的ACE抑制劑包括Lisinopril、Enalapril和Ramipril。副作用包括乾咳、頭暈和腎臟問題。服用ACE抑制劑的患者定期進行檢查以監測腎功能和鉀水平非常重要。 ACE抑制劑在減輕血管收縮素II的作用方面發揮關鍵作用，它們有助於舒張血管並同時調節體液儲存，從而顯著降低血壓。

市場動態

全球血管收縮素轉化酵素(ACE) 抑制劑市場的成長歸因於高血壓和心臟病在全球範圍內的高發生率。人體內會產生四種不同形式的血管收縮素（發音為 an-gee-oh-ten-sin，每種類型均以羅馬數字命名）。血管收縮素I 在 ACE 抑制劑的作用下轉化為血管收縮素II，後者在體內發揮多種作用。 ACE 抑制劑常被推薦用於治療心血管疾病和高血壓。 2019 年，超過 1,290 萬名聯邦醫療保險 D 部分 (Medicare Part D)用戶（約佔 D 部分所有受益人的 27%）被處方了 ACE 抑制劑。當然，ACE 抑制劑也可能產生副作用。大多數副作用較輕微，但有些副作用可能很危險，需要緊急醫療救助。

本研究的關鍵特徵

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數創建了全球血管收縮素轉化酵素(ACE) 抑制劑市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球血管收縮素轉化酵素（ACE）抑制劑市場報告」旨在為該行業的各種相關人員提供服務，包括經銷商、供應商、產品製造商、分銷商、新參與企業和金融分析師。
相關人員可以透過分析全球血管收縮素轉化酵素(ACE) 抑制劑市場中使用的各種策略矩陣輕鬆做出決策。

市場動態
- 促進因素
  - 高血壓盛行率增加
  - 活性化研發活動
  - 人們對心血管健康的認知不斷提高
- 抑制因子
  - 專利到期
  - 副作用和安全問題
  - 副作用和安全問題
- 機會
  - 人們對心血管健康的認知不斷提高
  - 個人化醫療
  - 聯合治療
影響分析
監管趨勢
產品上市及核准
PEST分析
波特的分析
併購情景

第4章全球血管收縮素轉化酵素（ACE）抑制劑市場：依藥物分類，2021-2033年

Benazepril
Perindopril
群多普利
Captopril
Enalapril
Lisinopril
其他（例如Ramipril等）

第5章全球血管收縮素轉化酵素（ACE）抑制劑市場：依適應症分類，2021-2033年

高血壓
缺血性心臟疾病
心臟衰竭
慢性腎臟病
硬皮症
其他（偏頭痛等）

第6章全球血管收縮素轉化酵素（ACE）抑制劑市場：依給藥途徑分類，2021-2033年

口服
注射

第7章全球血管收縮素轉化酵素（ACE）抑制劑市場：依通路分類，2021-2033年

醫院藥房
零售藥房
網路藥房

第8章全球血管收縮素轉化酵素（ACE）抑制劑市場：按地區分類，2021-2033年

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東和非洲
- GCC
- 以色列
- 北非
- 中非
- 其他中東和非洲國家

第9章競爭情勢

Novartis AG
Pfizer Inc.
Merck & Co.
AstraZeneca
Sanofi
Boehringer Ingelheim
GlaxoSmithKline
Lupin Limited
Torrent Pharmaceuticals Ltd.
Reddy's Laboratories Ltd.
Mylan

第10章

調查方法
關於本公司

簡介目錄

Product Code: CMI2746

Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,522.3 Mn in 2026 and is expected to reach USD 14,130.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9,522.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.80%	2033 Value Projection:	USD 14,130 Mn

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.

Market Segmentation

By Drugs (Revenue, USD Mn, 2021 - 2033)
Benazepril
Perindopril
Trandfolapril
Captopril
Enalapril
Lisinopril
Others (Ramipril, etc.)
By Indication (Revenue, USD Mn, 2021 - 2033)
Hypertension
Coronary Artery Disease
Heart Failure
Chronic Kidney Disease
Scleroderma
Others (Migraine, etc.)
By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Injectable
By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
Novartis AG
Pfizer Inc.
Merck & Co.
AstraZeneca
Sanofi
Boehringer Ingelheim
GlaxoSmithKline
Lupin Limited
Torrent Pharmaceuticals Ltd.
Reddy's Laboratories Ltd.
Mylan
Other Prominent Players

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Rising prevalence of hypertension
  - Growing Research and Development Activities
  - Increasing Awareness of Cardiovascular Health
- Restraints
  - Patent Expirations
  - Side Effects and Safety Concerns
  - Side Effects and Safety Concerns
- Opportunities
  - Increasing Awareness of Cardiovascular Health
  - Personalized medicine
  - Combination therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - North Africa
  - Central Africa
  - Rest of Middle East & Africa

9. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views